CNS Pharmaceuticals (CNSP) AI Stock Analysis

• Market Cap: $3.85M
• Dividend Yield: N/A
• Average Volume (3M): 16.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.46
• Revenue Growth: N/A
• EPS Growth: 99.87%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.76
• Shares Outstanding: 620,290
• 10 Day Avg. Volume: 15,052
• 30 Day Avg. Volume: 16,543
• PEG Ratio: 0.04
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.34
• Enterprise Value/Market Cap: -1.25
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.24K
• Enterprise Value/Ebitda: 0.37
• 1Y Price Target: $20.00
• Price Target Upside: 232.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $7.00 ▲(16.47% Upside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and sizeable cash burn indicating continued financing needs), partially offset by low balance-sheet leverage. Technicals are modestly supportive in the near term (above key short/intermediate moving averages), but longer-term trend and MACD remain weak, and valuation is constrained by negative earnings.

Positive Factors

Low Balance-Sheet Leverage

Very low reported debt provides durable financial flexibility and reduces bankruptcy risk compared with heavily levered peers. For a pre-revenue biotech, minimal interest burden preserves cash runway and strategic optionality to fund trials or pursue partnerships over the coming 2–6 months.

Focused CNS Oncology Pipeline

A concentrated pipeline focused on CNS malignancies, with a lead glioblastoma program, targets an area of high unmet need and limited competition. This specialization supports deep domain expertise, clearer regulatory paths, and partnership or licensing appeal that can sustain value creation beyond short-term market moves.

Increased Authorized Shares Provides Capital Flexibility

A shareholder-approved increase in authorized shares creates a structural capability to raise equity or issue stock for partnerships and acquisitions. For a cash-burning, pre-commercial biotech, this institutional flexibility materially eases future financing execution and strategic transactions over the medium term.

Negative Factors

High Cash Burn

Sustained TTM cash outflows near $16.2M indicate ongoing consumption of resources that will require external funding. Continued cash burn elevates dilution risk and constrains long-term R&D and trial execution unless the company secures durable financing or revenue, posing structural funding pressure.

No Revenue / Structural Losses

Absence of revenue and persistent net losses reflect a pre-commercial model that cannot self-fund operations. Until clinical success and commercialization occur, the business remains dependent on capital markets or partners, limiting resilience and increasing execution and dilution risk for shareholders.

Very Small Employee Base

A team of four suggests constrained internal capacity to manage clinical programs, regulatory interactions, and commercialization planning. Reliance on external contractors or partners increases operating and execution risk, potentially slowing development timelines and complicating coordination across critical functions.

CNS Pharmaceuticals Business Overview & Revenue Model

Company Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

How the Company Makes Money

CNS Pharmaceuticals primarily generates revenue through licensing agreements, research grants, and potential future sales of its drug candidates upon successful clinical trials and regulatory approval. The company may enter into strategic partnerships or collaborations with larger pharmaceutical companies to co-develop and commercialize its products, which can provide upfront payments, milestone payments, and royalties. Additionally, CNS Pharmaceuticals may raise capital through equity offerings to fund its research and development activities, which is a common practice in the biotechnology industry given the long development timelines and high costs associated with bringing new drugs to market.

CNS Pharmaceuticals Financial Statement Overview

Summary

CNS Pharmaceuticals is in the early development stage, reflected by its lack of revenue and consistent net losses. While the company has maintained liquidity through financing activities, its financial statements reveal challenges in achieving profitability and stability. Investors should be aware of the high-risk, high-reward nature typical of biotechnology firms at this stage.

Income Statement

CNS Pharmaceuticals has consistently reported zero revenue over the years, which is common in the biotechnology industry during the development phase. However, this results in negative profitability metrics, including net profit margins and EBIT/EBITDA margins, as the company incurs expenses without generating revenue. The lack of revenue growth highlights ongoing challenges in achieving commercial success.

Balance Sheet

The balance sheet shows a high level of cash and short-term investments relative to total assets, reflecting a strong liquidity position. However, the company has experienced a decline in stockholders' equity over the years, with negative equity in 2023. The debt-to-equity ratio is unstable due to negative equity, and the equity ratio has deteriorated, indicating potential financial instability.

Cash Flow

The company consistently reports negative operating and free cash flows, which is typical for a biotech firm in the R&D phase. Despite significant financing inflows, cash flow metrics such as the operating cash flow to net income and free cash flow to net income ratios remain negative, indicating ongoing cash burn and reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.88K	-3.31K	-4.13K	-11.76K	-13.07K	-11.10K
EBITDA	-13.05M	-14.84M	-18.86M	-15.26M	-14.47M	-9.44M
Net Income	-13.07M	-14.86M	-18.85M	-15.27M	-14.50M	-9.46M
Balance Sheet
Total Assets	11.87M	8.70M	1.70M	13.05M	8.76M	15.85M
Cash, Cash Equivalents and Short-Term Investments	9.86M	6.46M	548.72K	10.06M	5.00M	14.04M
Total Debt	30.79K	326.07K	300.81K	409.97K	387.79K	439.29K
Total Liabilities	1.96M	2.52M	6.13M	4.92M	2.14M	1.91M
Stockholders Equity	9.91M	6.18M	-4.43M	8.13M	6.62M	13.95M
Cash Flow
Free Cash Flow	-16.23M	-17.12M	-14.14M	-10.56M	-13.54M	-7.34M
Operating Cash Flow	-16.23M	-17.11M	-14.14M	-10.56M	-13.54M	-7.32M
Investing Cash Flow	-4.19K	-4.19K	-3.90K	-4.42K	-5.75K	-17.95K
Financing Cash Flow	19.13M	23.03M	4.64M	15.61M	4.51M	14.13M

CNS Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSP, the sentiment is Positive. The current price of 6.01 is above the 20-day moving average (MA) of 6.01, below the 50-day MA of 6.52, and below the 200-day MA of 9.15, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 65.74 is Neutral, neither overbought nor oversold. The STOCH value of 70.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNSP.

CNS Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSP	46 Neutral	$3.85M	-0.13	-197.11%	―	―	99.87%
SLRX	44 Neutral	$5.23M	-0.02	-139.55%	―	―	68.08%
INM	44 Neutral	$3.17M	-0.15	-82.17%	―	-3.27%	51.83%
GRI	42 Neutral	$3.32M	-0.02	-397.84%	―	―	98.22%
BDRX	41 Neutral	$1.29M	-0.03	-60.37%	―	-100.00%	86.75%
OGEN	29 Underperform	$3.83M	-0.06	-168.95%	―	―	90.27%

CNS Pharmaceuticals Corporate Events

CNS Pharmaceuticals Announces New CEO Appointment

On December 16, 2025, CNS Pharmaceuticals announced a leadership transition with the appointment of Rami Levin as Chief Executive Officer and President, effective January 1, 2026. Mr. Levin brings extensive experience from leadership roles in biopharmaceutical companies and will also join the Board of Directors. His compensation package includes a base salary, performance-based bonuses, and equity grants. Additionally, the company confirmed the resignation of John Climaco from his roles as CEO and board member on December 16, 2025. Mr. Climaco’s departure is amicable, and he will receive severance benefits, including salary, bonus payments, and medical coverage.

The most recent analyst rating on (CNSP) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CNS Pharmaceuticals stock, see the CNSP Stock Forecast page.

CNS Pharmaceuticals Increases Authorized Shares for Growth

On November 17, 2025, CNS Pharmaceuticals held its Annual Meeting where stockholders approved several key proposals, including an amendment to the Articles of Incorporation to significantly increase the number of authorized shares of common and preferred stock. This move, filed on November 20, 2025, with the Nevada Secretary of State, is expected to enhance the company’s capital structure and provide greater flexibility for future growth and investment opportunities.

The most recent analyst rating on (CNSP) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CNS Pharmaceuticals stock, see the CNSP Stock Forecast page.